Sales 2024 * | 69Cr 5.77TCr | Sales 2025 * | 85Cr 7.09TCr | Capitalization | 307.37Cr 26TCr |
---|---|---|---|---|---|
Net income 2024 * | -10Cr -876.75Cr | Net income 2025 * | - 0 | EV / Sales 2024 * | 4.08 x |
Net cash position 2024 * | 26Cr 2.14TCr | Net cash position 2025 * | 38Cr 3.2TCr | EV / Sales 2025 * | 3.17 x |
P/E ratio 2024 * |
-28.4
x | P/E ratio 2025 * |
258
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.15% |
Latest transcript on HUTCHISON CHINA MED.
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 01/05/01 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 01/08/01 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Graeme Jack
BRD | Director/Board Member | 73 | 01/17/01 |
Dan Eldar
CHM | Chairman | 70 | 01/16/01 |
Edith Shih
BRD | Director/Board Member | 71 | 01/00/01 |
1st Jan change | Capi. | |
---|---|---|
+45.82% | 77TCr | |
+40.95% | 63TCr | |
-6.16% | 35TCr | |
+19.86% | 33TCr | |
+9.32% | 30TCr | |
+18.45% | 25TCr | |
-0.78% | 22TCr | |
+11.88% | 22TCr | |
+5.90% | 16TCr |